Compare EDUC & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDUC | SNGX |
|---|---|---|
| Founded | 1965 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 7.6M |
| IPO Year | 1995 | 2006 |
| Metric | EDUC | SNGX |
|---|---|---|
| Price | $0.87 | $0.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | ★ $1.38 |
| AVG Volume (30 Days) | 33.8K | ★ 161.2K |
| Earning Date | 01-07-2027 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.86 | 57.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,913,600.00 | $119,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.81 | $0.23 |
| 52 Week High | $1.65 | $3.39 |
| Indicator | EDUC | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 21.75 | 16.37 |
| Support Level | $0.81 | N/A |
| Resistance Level | $1.36 | $0.82 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 14.40 | 7.77 |
Educational Development Corp distributes books and educational products and publications through its PaperPie and EDC Publishing divisions to individual consumers, book, toy and gift stores, libraries and home educators located throughout the United States. The company is the owner and exclusive publisher of Kane Miller children's books; Learning Wrap-Ups, maker of educational manipulatives; and SmartLab Toys, maker of STEAM-based toys and games. Multi-Level Marketing (MLM) distributor of Usborne Publishing Limited (Usborne) children's books. It sell children's books, educational toys and games and other related products. It has two reportable segments: PaperPie and Publishing of which majority of revenue comes from Paperpie Segment.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).